Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Raw Materials (2018 - 2026)

TransMedics has reported Raw Materials over the past 8 years, most recently at $26.2 million for Q4 2025.

  • For Q4 2025, Raw Materials fell 6.34% year-over-year to $26.2 million; the TTM value through Dec 2025 reached $26.2 million, down 6.34%, while the annual FY2025 figure was $26.2 million, 6.34% down from the prior year.
  • Raw Materials for Q4 2025 was $26.2 million at TransMedics, up from $20.3 million in the prior quarter.
  • Over five years, Raw Materials peaked at $28.0 million in Q3 2024 and troughed at $6.1 million in Q1 2021.
  • A 5-year average of $16.8 million and a median of $17.0 million in 2023 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: skyrocketed 136.06% in 2023 and later tumbled 30.35% in 2025.
  • Year by year, Raw Materials stood at $7.3 million in 2021, then soared by 50.38% to $10.9 million in 2022, then skyrocketed by 136.06% to $25.8 million in 2023, then increased by 8.54% to $28.0 million in 2024, then dropped by 6.34% to $26.2 million in 2025.
  • Business Quant data shows Raw Materials for TMDX at $26.2 million in Q4 2025, $20.3 million in Q3 2025, and $19.2 million in Q2 2025.